Starpharma see impressive results for colon cancer drug

Company News

by Rachael Jones

Starpharma (ASX:SPL) have released impressive results for their DEP irinotecan nanoparticle formulation for colon cancer. 

The formulation showed significant efficacy and safety benefits over leading colorectal cancer drugs Camptosar and Erbitux.

Irinotecan (Camptosar®) is used as a component of first line therapy for the treatment of CRC, which is one of the most common cancers in the world, affecting more than 1 million individuals annually and is the third-leading cause of cancer-related death.

Starpharma (ASX:SPL) are trading 5.1 per cent higher at $1.36.

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.